These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23796729)

  • 21. Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS).
    Chen CH; Lim SJ; Oh JK; Huang TW; Zeng YH; Wu MT; Yang HL; Cheung JP; Kim JW; Han JH; Huo L; Lin TJ; Zhou G; Wu WS
    Clin Interv Aging; 2020; 15():111-121. PubMed ID: 32099341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
    Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
    Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
    Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.
    Briot K; Ravaud P; Dargent-Molina P; Zylberman M; Liu-Leage S; Roux C
    Osteoporos Int; 2009 Apr; 20(4):625-30. PubMed ID: 18661089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide.
    Lau AN; Ali SH; Sawka AM; Thabane L; Papaioannou A; Gafni A; Adachi JD
    BMC Musculoskelet Disord; 2008 Nov; 9():151. PubMed ID: 18990249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures.
    Kwon BT; Ham DW; Park SM; Kim HJ; Yeom JS
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202595
    [No Abstract]   [Full Text] [Related]  

  • 30. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
    Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
    Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
    Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
    Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
    Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
    Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Impact of Teriparatide on Quality of Life in Osteoporotic Patients].
    Osca Guadalajara M; Guadalajara Olmeda N; Escartín Martínez R
    Rev Esp Salud Publica; 2015 Apr; 89(2):215-25. PubMed ID: 26121630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
    Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
    Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
    Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Kiel DP; Reginster JY; Dore RK; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006; 17(11):1630-7. PubMed ID: 16896507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.